Nasykhova YA, Barbitoff YA, Serebryakova EA, Katserov DS, Glotov AS. Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes. World J Diabetes 2019; 10(7): 376-395 [PMID: 31363385 DOI: 10.4239/wjd.v10.i7.376]
Corresponding Author of This Article
Andrey S Glotov, DSc, PhD, Head of Department, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynaecology and Reproductology, Mendeleevskaya Line 3, St. Petersburg 199034, Russia. anglotov@mail.ru
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jul 15, 2019; 10(7): 376-395 Published online Jul 15, 2019. doi: 10.4239/wjd.v10.i7.376
Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes
Yulia A Nasykhova, Yury A Barbitoff, Elena A Serebryakova, Dmitry S Katserov, Andrey S Glotov
Yulia A Nasykhova, Yury A Barbitoff, Andrey S Glotov, Laboratory of Biobanking and Genomic Medicine of Institute of Translation Biomedicine, St. Petersburg State University, St. Petersburg 199034, Russia
Yulia A Nasykhova, Elena A Serebryakova, Andrey S Glotov, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynaecology and Reproductology, St. Petersburg 199034, Russia
Yury A Barbitoff, Bioinformatics Institute, St. Petersburg 194021, Russia
Yury A Barbitoff, Department of Genetics and Biotechnology, St. Petersburg State University, St. Petersburg 199034, Russia
Elena A Serebryakova, Andrey S Glotov, Department of Genetics, City Hospital No. 40, St. Petersburg 197706, Russia
Dmitry S Katserov, Andrey S Glotov, Institute of Living Systems, Immanuel Kant Baltic Federal University, Kaliningrad 236016, Russia
Author contributions: All authors contributed equally to the work.
Supported byD.O. Ott Research Institute of Obstetrics, Gynaecology and Reproductology, project 558-2019-0012 (АААА-А19-119021290033-1) of FSBSI.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Andrey S Glotov, DSc, PhD, Head of Department, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynaecology and Reproductology, Mendeleevskaya Line 3, St. Petersburg 199034, Russia. anglotov@mail.ru
Telephone: +7-911-7832003 Fax: +7-812-3280262
Received: February 21, 2019 Peer-review started: February 22, 2019 First decision: May 8, 2019 Revised: May 23, 2019 Accepted: June 11, 2019 Article in press: June 11, 2019 Published online: July 15, 2019 Processing time: 144 Days and 16.1 Hours
Abstract
Type 2 diabetes (T2D) mellitus is a common complex disease that currently affects more than 400 million people worldwide and has become a global health problem. High-throughput sequencing technologies such as whole-genome and whole-exome sequencing approaches have provided numerous new insights into the molecular bases of T2D. Recent advances in the application of sequencing technologies to T2D research include, but are not limited to: (1) Fine mapping of causal rare and common genetic variants; (2) Identification of confident gene-level associations; (3) Identification of novel candidate genes by specific scoring approaches; (4) Interrogation of disease-relevant genes and pathways by transcriptional profiling and epigenome mapping techniques; and (5) Investigation of microbial community alterations in patients with T2D. In this work we review these advances in application of next-generation sequencing methods for elucidation of T2D pathogenesis, as well as progress and challenges in implementation of this new knowledge about T2D genetics in diagnosis, prevention, and treatment of the disease.
Core tip: Next-generation sequencing (NGS) technologies have a broad range of applications in studying the genetic causes of type 2 diabetes (T2D), such as: (1) Identification of rare and common genetic variants, associated with disease; (2) Functional studies for describing role of genes in disease pathogenesis; and (3) Evaluation of environmental contribution to the disease by using microbiome profiling methods. This review of NGS application to the genetic research of T2D presents the advances and challenges related with sequencing analysis-based studies and implementation of this knowledge in clinical practice.
